Related Experiment Videos
Magnetic resonance spectroscopy in hypoxic-ischemic encephalopathy
1Department of Neurology, University of Pennsylvania, Philadelphia.
Summary
Magnetic resonance spectroscopy (MRS) noninvasively measures brain metabolites in newborns. In severe hypoxic-ischemic encephalopathy, altered metabolite ratios correlate with neurodevelopmental outcomes, aiding treatment decisions.
Area of Science:
- Neuroscience
- Medical Imaging
- Biochemistry
Background:
- In vivo magnetic resonance spectroscopy (MRS) enables noninvasive, serial measurement of key cerebral metabolites.
- MRS is crucial for studying neonatal neurologic disorders, particularly metabolic changes.
Purpose of the Study:
- To investigate the utility of MRS in assessing cerebral metabolic alterations in neonatal hypoxic-ischemic encephalopathy (HIE).
- To correlate metabolic changes detected by MRS with neurodevelopmental outcomes in affected infants.
Main Methods:
- Utilized in vivo magnetic resonance spectroscopy (MRS) to measure metabolites like ATP, phosphocreatine (PCr), and inorganic phosphate (Pi).
- Analyzed changes in metabolite ratios (PCr/Pi, PCr/ATP, Pi/ATP) and intracellular pH.
- Correlated MRS findings with neurodevelopmental outcomes in neonates with HIE.
Main Results:
- Severe HIE showed decreased PCr and increased Pi, leading to altered PCr/Pi and PCr/ATP ratios, and increased Pi/ATP.
- These metabolic shifts significantly correlated with neurodevelopmental outcomes.
- Markedly decreased ATP was observed only in extremely severe HIE cases, often preceding neonatal death.
Conclusions:
- Serial MRS studies can identify neonates with HIE who may benefit from targeted interventional treatments.
- MRS is a valuable tool for monitoring disease severity and predicting outcomes in neonatal neurologic disorders.
- Advancements in MRS technology promise enhanced localization and multinuclear capabilities for improved metabolic assessment.